• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Drugmakers may face FDA fines for slow efficacy confirmation in cancer drugs

Drugmakers may face FDA fines for slow efficacy confirmation in cancer drugs

March 28, 2011
CenterWatch Staff

Winning early U.S. approval of promising cancer treatments could wind up costing drugmakers up to $10 million in fines if they don’t confirm their drugs’ effectiveness in follow-up studies within a restrictive timeframe, FDA officials said, according to a Bloomberg report.

Before a drug can win expedited approval, the FDA may also start requiring that follow-up trials be underway, John Johnson, a clinical team leader at the agency’s Division of Drug Oncology Products, and colleagues said in a report published online in the Journal of the National Cancer Institute.

The agency’s accelerated-approval program came under scrutiny last year when New York-based Pfizer, the world’s biggest drugmaker, withdrew its leukemia drug Mylotarg after 10 years on the U.S. market and the FDA moved to revoke its 2008 clearance of Basel, Switzerland-based Roche’s Avastin for breast cancer. A drug can be pulled if subsequent studies don’t show it prolongs survival or improves quality of life.

Follow-up studies had yet to be completed as of last July for 14 accelerated approvals granted over the past 12 years, according to the report. Among them was the 1999 clearance of Pfizer’s arthritis drug Celebrex to treat a rare colon condition and a 2005 approval of London-based GlaxoSmithKline’s Arranon for lymphoma, the authors said.

The agency could confirm efficacy faster by requiring that such trials be in progress before granting an accelerated approval, the report said.

A 2007 law authorized the FDA to fine drugmakers as much as $10 million for “lack of due diligence” in conducting trials to confirm the benefits of drugs that win accelerated approval, according to the report.

“The FDA believes that this will be an effective new tool for dealing with lack of due diligence,” Johnson and his colleagues wrote.

As quoted in MedPage Today, Susan Ellenberg, Ph.D., of the University of Pennsylvania, wrote that the FDA is "routinely castigated for proceeding too cautiously and slowly, and at the same time, for rushing drugs to market too rapidly without adequate study."

"What some might consider a happy medium will inevitably leave many other scientists, clinicians and consumers dissatisfied," she wrote, citing the example of bevacizumab (Avastin) for breast cancer.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Revamp-360x240.png

    Califf Calls for Major Evidence Generation Revamp, Experts’ Opinions Differ

  • AskTheExpertsGreen-360x240.png

    Ask the Experts: Managing Investigational Products

  • SurveywBlueBackground-360x240.png

    Survey Outlines Site Challenges, Successes on Diversity

  • PatientCentricity-360x240.png

    Site Spotlight: DM Clinical Shows Patient Centricity Doesn’t Have to Break the Bank

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing